KRYSTAL-1

NCT03785249 📎

Regimen

Experimental: adagrasib
Control: none

Population

KRAS G12C pre-treated NSCLC

Key finding

ORR 42.9% (33.5-52.6); mPFS 6.5 mo; CNS penetration better than sotorasib

Source: PMID 35658005

Timeline

Enrollment start: 2019-01-15 📎

Guideline citations

NCCN NSCLC Version 5.2026 (p.207)
CSCO NSCLC 2025 ⚠️ OCR source